LifeMD Reports Fourth Quarter and Full Year 2025 Results

Rhea-AI Summary

LifeMD (Nasdaq: LFMD) reported full year 2025 revenue of $194.1 million (up 25%) and adjusted EBITDA of $15.3 million (up 309%). Q4 revenue was $46.9 million (+4%) with adjusted EBITDA of $4.8 million (+348%).

The company exited 2025 with $36.8 million cash, no debt, ~323,000 active subscribers, a benefits infrastructure to cover ~220 million Americans by Q2, and a post‑year‑end launch of oral Wegovy with >80% initiation among new weight management patients.

Positive

• Full year revenue +25% to $194.1M
• Adjusted EBITDA +309% to $15.3M for 2025
• Quarterly active subscribers +16% to ~323,000
• Exited year with $36.8M cash and no debt
• Benefits infrastructure on track to cover ~220M Americans by Q2
• Post‑year‑end oral Wegovy launch with >80% initiation among new weight management patients

Negative

• Q1 2026 expected adjusted EBITDA loss of $4M–$5M due to front‑loaded patient acquisition spend
• First‑quarter investment pace may pressure near‑term profitability before Q2 recovery

Key Figures

FY 2025 Revenue: $194.1 million FY 2025 Adjusted EBITDA: $15.3 million Q4 2025 Revenue: $46.9 million +5 more

8 metrics

FY 2025 Revenue $194.1 million Full year 2025, up 25% year-over-year

FY 2025 Adjusted EBITDA $15.3 million Full year 2025, up 309% year-over-year

Q4 2025 Revenue $46.9 million Fourth quarter 2025, 4% year-over-year growth

Q4 2025 Adjusted EBITDA $4.8 million Fourth quarter 2025, up 348% year-over-year

Cash Balance $36.8 million Cash as of December 31, 2025; company reported no debt

Active Subscribers 322,872 Active telehealth subscribers at Q4 2025 quarter end, up 16%

Gross Margin 87% Q4 2025 gross margin, up from 81% in prior-year period

GAAP Net Loss (cont. ops) $1.9 million ($0.04/share) Q4 2025 net loss from continuing operations attributable to common stockholders

Market Reality Check

Price: $3.12 Vol: Volume 948,550 is 1.09x t...

normal vol

$3.12 Last Close

Volume Volume 948,550 is 1.09x the 20-day average of 872,942 shares. normal

Technical Price at $3.00 is well below the $6.69 200-day MA and 81.06% below the 52‑week high.

Peers on Argus

Peers show mixed moves (e.g., HCAT +4.84%, SOPH -1.14%) and no names in the mome...

Peers show mixed moves (e.g., HCAT +4.84%, SOPH -1.14%) and no names in the momentum scanner, suggesting today’s setup is more LFMD-specific than a sector-wide rotation.

Previous Earnings Reports

5 past events · Latest: Nov 17 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 17	Q3 2025 earnings	Positive	-13.5%	Reported Q3 revenue and adjusted EBITDA growth with debt paydown and divestiture.
Aug 05	Q2 2025 earnings	Negative	-44.9%	Strong Q2 growth but reduced full-year 2025 revenue and EBITDA guidance outlook.
Aug 04	Peer MED earnings	Negative	-4.1%	Medifast reported revenue declines and coach attrition, facing GLP-1 headwinds.
May 06	Q1 2025 earnings	Positive	+3.2%	First GAAP-profitable quarter with strong revenue growth and raised 2025 guidance.
Apr 28	Peer MED earnings	Negative	+41.3%	Medifast posted revenue declines and losses yet saw a strong positive price move.

Pattern Detected

Across recent earnings events, LFMD often saw negative or volatile price moves even on strong growth metrics, with an average move of -3.6%.

Recent Company History

Over the past year, LifeMD’s earnings reports highlighted rapid revenue growth, margin expansion, and a transition to pure-play telehealth. Q1 and Q2 2025 showed strong top-line gains and improving adjusted EBITDA, though Q2 included a guidance reduction. Q3 2025 results featured debt paydown and the WorkSimpli divestiture. The Wegovy pill collaboration and telehealth subscriber growth positioned LifeMD for GLP‑1–driven expansion. Today’s Q4 and full‑year 2025 report extends that trajectory with higher revenue, sharply higher adjusted EBITDA, and a cash-rich, debt-free balance sheet.

Historical Comparison

-3.6% avg move · Over five recent earnings events, average next‑day move was -3.6%, with mixed alignment between stro...

earnings

-3.6%

Average Historical Move earnings

Over five recent earnings events, average next‑day move was -3.6%, with mixed alignment between strong fundamentals and share-price reactions.

Earnings across 2025 showed sustained revenue and EBITDA growth, a shift to pure-play telehealth, debt payoff, and guidance resets, culminating in today’s full‑year 2025 results and 2026 outlook.

Market Pulse Summary

This announcement highlights FY 2025 revenue of $194.1M (+25%) and adjusted EBITDA of $15.3M (+309%)...

Analysis

This announcement highlights FY 2025 revenue of $194.1M (+25%) and adjusted EBITDA of $15.3M (+309%), alongside Q4 gross margin of 87% and year-end cash of $36.8M with no debt. Active subscribers reached 322,872, and management issued 2026 revenue guidance of $220–230M. Historically, earnings events averaged a -3.6% move, underscoring the importance of tracking GLP‑1 patient growth, women’s health adoption, and delivery versus guidance through 2026.

Key Terms

adjusted EBITDA, GLP-1, telehealth, GAAP, +1 more

5 terms

adjusted EBITDA financial

"Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309%..."

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

GLP-1 medical

"More than 100 million Americans are clinically eligible for GLP-1 therapy..."

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

telehealth technical

"In our first quarter as a pure-play telehealth business, LifeMD delivered solid results..."

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

GAAP financial

"The company achieved its first-ever quarter of GAAP profitability..."

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

run-rate financial

"annualized run-rate revenue expected to exceed $250 million by Q4 2026..."

Run-rate is an estimate of a company’s future annual performance created by multiplying recent results (such as a month or quarter) to project a full year, like using current speed to guess how far you’ll travel in a year. Investors use it as a quick way to gauge growth, size and momentum and to compare firms, but it can be misleading if recent results include one-time events or seasonal swings, so it’s a rough, not definitive, forecast.

AI-generated analysis. Not financial advice.

• Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.
• Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.
• Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels.
• Exited 2025 with $36.8 million of cash and no debt, positioning LifeMD for accelerated investments in growth.
• Benefits infrastructure on track to cover approximately 220 million Americans in second quarter; women’s health offering seeing strong early patient growth.

Conference call begins at 4:30 p.m. Eastern time today

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the fourth quarter and year ended December 31, 2025.

Management Commentary

“LifeMD delivered strong fourth quarter results across all business lines and is entering its next phase of growth,” said Justin Schreiber, Chairman and CEO of LifeMD. “Our strategy of building a trusted and sustainable platform for virtual healthcare delivery is gaining momentum. Our weight management business is seeing record patient sign-ups in the first quarter at attractive acquisition costs. More than 100 million Americans are clinically eligible for GLP-1 therapy, yet only a fraction are currently being treated—a generational opportunity. Subsequent to year end, we launched oral Wegovy to help patients overcome real barriers around cost, access, and ongoing clinical support. With multiple catalysts ahead—including Medicare coverage for GLP-1 medications, expanded collaborations with GLP-1 manufacturers, and an infrastructure that supports both self-pay and insurance—LifeMD is uniquely positioned for long-term leadership in this transformative market.

“Beyond weight management, our highly differentiated specialty offerings continue to scale. Rex MD, our men’s health brand, delivered strong, profitable growth and recently launched oral Wegovy. Our women’s health business, focused on menopause, hormonal, and bone health, is seeing encouraging early patient growth and represents a deeply underserved population we are uniquely equipped to help. Underpinning all of this is a virtual care infrastructure that we believe sets LifeMD apart and positions the Company for success in the years to come: a 50-state medical benefits infrastructure expected to cover 220 million Americans by end of the second quarter, a highly specialized affiliated provider group, and a national affiliated pharmacy operation. This foundation, combined with unique and growing collaborations with some of the largest healthcare and pharmaceutical brands in the world, uniquely positions LifeMD to capture significant growth in 2026 and the years ahead,” concluded Mr. Schreiber.

“In our first quarter as a pure-play telehealth business, LifeMD delivered solid results with 4% revenue growth and a 348% increase in adjusted EBITDA. Our balance sheet has never been stronger—we exited the year with nearly $37 million in cash and no debt. This financial strength is a key asset as we invest aggressively in the expansion of our rapidly growing and diversifying platform. Our 2026 guidance reflects these investments, with annualized run-rate revenue expected to exceed $250 million and annualized adjusted EBITDA expected to exceed $25 million by the fourth quarter of 2026,” said Marc Benathen, LifeMD’s Chief Financial Officer.

Fourth Quarter Financial Highlights

All comparisons are with the fourth quarter of 2024. Non-GAAP financial measures referenced below are defined and reconciled to GAAP financial measures at the end of this press release.

• Total revenue increased 4% to $46.9 million.
• The number of active telehealth subscribers increased 16% to approximately 323,000 at quarter end.
• Gross margin expanded to 87%, up from 81% in the prior-year period, reflecting favorable revenue mix.
• GAAP net loss from continuing operations attributable to LifeMD, Inc. common stockholders was $1.9 million or $0.04 per share compared to a net loss from continuing operations attributable to LifeMD, Inc. common stockholders of $6.8 million or ($0.16) per share in the prior-year period.
• Including income from discontinued operations related to the sale of WorkSimpli, net income totaled $19.2 million, or $0.41 per share.
• Adjusted EBITDA was $4.8 million compared to $1.1 million in the prior-year period.
• Cash totaled $36.8 million as of December 31, 2025 and the Company had no debt as of year-end 2025.
  
  

Fourth Quarter Key Performance Metrics

($ in 000s)	Three Months Ended Dec. 31,					Y-o-Y			Twelve Months Ended Dec. 31,					Y-o-Y
Key Performance Metrics	2025		2024			% Growth			2025		2024			% Growth
Revenue
Revenue	$	46,868	$	45,137		4	%		$	194,055	$	154,824		25	%
Adjusted EBITDA	$	4,759	$	1,062		348	%		$	15,254	$	3,726		309	%
Active Subscribers		322,872		277,739		16	%			322,872		277,739		16	%

Financial Guidance

For the first quarter of 2026, the Company expects:

• Revenue in the range of $48 million to $49 million.
• Adjusted EBITDA loss of $4 million to $5 million, reflecting strategic front-loaded patient acquisition investment spend as the number of GLP-1 patient sign-ups doubled versus Q4 2025.
• Adjusted EBITDA expected to return to profitability in Q2 as customer acquisition costs decline sequentially and the substantial rise in patient volumes becomes accretive for the balance of 2026.
  

For the full year 2026, the Company expects:

• Revenue in the range of $220 million to $230 million, representing 13% to 19% year-over-year growth. Annualized run-rate revenue expected to exceed $250 million by Q4 2026, driven by GLP-1 and women’s health momentum.
• Adjusted EBITDA in the range of $12 million to $17 million. Annualized run-rate adjusted EBITDA expected to exceed $25 million by Q4 2026, with substantial second-half accretion as weight management and women’s health investments mature.

Conference Call

LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:

Toll-free dial-in number: 800-343-5172
International dial-in number: 203-518-9856
Conference ID: LIFEMD

A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

About LifeMD, Inc.

LifeMD^® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com

Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com

Tables to Follow

LIFEMD, INC.
CONSOLIDATED BALANCE SHEETS
	December 31, 2025			December 31, 2024
ASSETS
Current Assets
Cash	$	36,786,318		$	32,651,801
Accounts receivable		9,305,277			10,455,813
Product deposit		320,217			40,763
Inventory, net		2,773,576			2,797,358
Other current assets		2,646,077			3,003,539
Current assets of discontinued operations		-			3,420,086
Total Current Assets		51,831,465			52,369,360
Non-current Assets
Equipment, net		2,444,717			1,439,573
Right of use assets, net		5,267,857			6,228,559
Capitalized software, net		10,604,946			9,305,919
Intangible assets, net		262,334			53,336
Non-current assets of discontinued operations		-			6,699,550
Total Non-current Assets		18,579,854			23,726,937
Total Assets	$	70,411,319		$	76,096,297
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable	$	14,149,154		$	10,904,671
Accrued expenses		15,974,016			21,756,619
Current operating lease liabilities		642,422			320,082
Current portion of convertible long-term debt		-			8,444,444
Deferred revenue		10,807,773			17,097,854
Current liabilities of discontinued operations		-			8,876,498
Total Current Liabilities		41,573,365			67,400,168
Long-term Liabilities
Convertible long-term debt, net		-			9,885,057
Non-current operating lease liabilities		5,681,374			6,279,004
Non-current liabilities of discontinued operations		-			86,188
Total Liabilities		47,254,739			83,650,417
Commitments and Contingencies
Stockholders’ Equity (Deficit)
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding as of December 31, 2025 and 2024		140			140
Common Stock, $0.01 par value; 100,000,000 shares authorized, 46,760,016 and 42,293,907 shares issued, 46,656,976 and 42,190,867 outstanding as of December 31, 2025 and 2024, respectively		467,600			422,939
Additional paid-in capital		251,455,616			230,508,339
Accumulated deficit		(228,603,075)			(239,850,931)
Treasury stock, 103,040 shares, at cost, as of December 31, 2025 and 2024		(163,701)			(163,701)
Total LifeMD, Inc. Stockholders’ Equity (Deficit)		23,156,580			(9,083,214)
Non-controlling interest of discontinued operations		-			1,529,094
Total Stockholders’ Equity (Deficit)		23,156,580			(7,554,120)
Total Liabilities and Stockholders’ Equity (Deficit)	$	70,411,319		$	76,096,297

LIFEMD, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
			Fourth Quarter Ended December 31,						Year Ended December 31,
			2025			2024			2025			2024
Telehealth revenue, net			$	46,868,484		$	45,137,021		$	194,055,198		$	154,824,075
Cost of telehealth revenue				6,025,408			8,391,484			27,714,808			21,440,799
Gross profit				40,843,076			36,745,537			166,340,390			133,383,276
Expenses
Selling and marketing expenses				19,086,443			17,819,834			86,074,473			70,102,961
General and administrative expenses				15,541,255			16,603,620			57,937,023			57,947,932
Customer service expenses				2,493,087			2,831,985			11,579,636			10,217,654
Other operating expenses				3,000,591			2,663,872			11,073,155			8,659,712
Development costs				1,819,418			1,670,906			7,345,797			6,857,005
Total expenses				41,940,794			41,590,217			174,010,084			153,785,264
Operating loss from continuing operations				(1,097,718)			(4,844,680)			(7,669,694)			(20,401,988)
Other expenses
Interest expense, net				24,079			(610,954)			(1,360,967)			(2,175,405)
Loss on debt extinguishment				-			-			(1,155,851)			-
Loss from continuing operations before income taxes				(1,073,639)			(5,455,634)			(10,186,512)			(22,577,393)
Income tax provision				(13,898)			(598,000)			(45,721)			(598,000)
Net loss from continuing operations				(1,087,537)			(6,053,634)			(10,232,233)			(23,175,393)
Net income from discontinued operations				21,030,505			1,426,807			25,852,024			2,315,252
Net income (loss)				19,942,968			(4,626,827)			15,619,791			(20,860,141)
Net (loss) income attributable to noncontrolling interests of discontinued operations				(20,697)			311,838			1,265,685			548,875
Net income (loss) attributable to LifeMD, Inc.				19,963,665			(4,938,665)			14,354,106			(21,409,016)
Preferred stock dividends				(776,562)			(776,562)			(3,106,250)			(3,106,250)
Net income (loss) attributable to LifeMD, Inc. common stockholders			$	19,187,103		$	(5,715,227)		$	11,247,856		$	(24,515,266)
Basic earnings (loss) per share attributable to LifeMD, Inc. common stockholders
Continuing operations			$	(0.04)		$	(0.16)		$	(0.30)		$	(0.64)
Discontinued operations				0.45			0.03			0.54			0.04
Basic earnings (loss) per share			$	0.41		$	(0.14)		$	0.25		$	(0.60)
Diluted earnings (loss) per share attributable to LifeMD, Inc. common stockholders
Continuing operations			$	(0.04)		$	(0.16)		$	(0.30)		$	(0.64)
Discontinued operations				0.45			0.03			0.54			0.04
Diluted earnings (loss) per share			$	0.41		$	(0.14)		$	0.25		$	(0.60)
Weighted average number of common shares outstanding:
Basic				46,773,743			42,205,767			45,129,617			41,196,292
Diluted				46,773,743			42,205,767			45,129,617			41,196,292

LIFEMD, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
		Fourth Quarter Ended December 31,						Year Ended December 31,
		2025			2024			2025			2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)		$	19,942,968		$	(4,626,827)		$	15,619,791		$	(20,860,141)
Less: Net income from discontinued operations			21,030,505			1,426,807			25,852,024			2,315,252
Net loss from continuing operations			(1,087,537)			(6,053,634)			(10,232,233)			(23,175,393)
Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities:
Amortization of debt discount			-			100,444			234,369			401,775
Amortization of capitalized software			1,636,200			1,481,039			6,348,932			5,696,865
Amortization of intangibles			31,918			6,666			94,002			26,667
Accretion of consideration payable			-			-			-			13,644
Depreciation of fixed assets			281,609			159,380			865,524			465,830
Write-down of inventory			-			675,669			-			675,669
Loss on debt extinguishment			-			-			1,155,851			-
Noncash operating lease expense			217,495			220,622			960,702			672,983
Stock compensation expense			2,655,143			3,104,956			10,496,321			12,234,797
Changes in Assets and Liabilities
Accounts receivable			(363,895)			661,327			1,150,536			(4,487,546)
Product deposit			50,301			95,992			(279,454)			445,087
Inventory			658,806			(827,584)			23,782			(713,095)
Other current assets			915,702			(121,682)			357,463			(2,270,374)
Operating lease liabilities			(103,449)			(13,780)			(275,290)			(381,189)
Deferred revenue			(1,340,226)			(933,283)			(6,290,081)			9,826,219
Accounts payable			(651,595)			1,043,605			3,244,483			4,176,113
Accrued expenses			(4,998,738)			662,521			(5,782,603)			10,755,261
Net cash (used in) provided by operating activities of continuing operations			(2,098,266)			262,258			2,072,304			14,363,313
Net cash (used in) provided by operating activities of discontinued operations			(1,182,257)			811,043			6,207,871			3,149,877
Net cash (used in) provided by operating activities			(3,280,523)			1,073,301			8,280,175			17,513,190
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for capitalized software costs			(1,763,287)			(1,601,100)			(7,647,959)			(6,738,742)
Purchase of equipment			(190,704)			(212,287)			(1,870,668)			(1,463,357)
Net cash used in investing activities of continuing operations			(1,953,991)			(1,813,387)			(9,518,627)			(8,202,099)
Net cash provided by (used in) investing activities of discontinued operations			19,023,623			(907,340)			16,426,858			(3,334,219)
Net cash provided by (used in) investing activities			17,069,632			(2,720,727)			6,908,231			(11,536,318)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of debt instruments			-			-			(18,719,721)			-
Sale of common stock under ATM, net			-			-			8,721,717			-
Repayment of notes payable, net of prepayment penalty			-			-			-			(327,597)
Cash proceeds from exercise of warrants			-			-			464,950			-
Cash proceeds from exercise of options			-			12,499			5,950			120,312
Preferred stock dividends			(776,562)			(776,562)			(3,106,250)			(3,106,250)
Net cash used in financing activities of continuing operations			(776,562)			(764,063)			(12,633,354)			(3,313,535)
Net cash used in financing activities of discontinued operations			(12,000)			(170,840)			(773,658)			(805,138)
Net cash used in financing activities			(788,562)			(934,903)			(13,407,012)			(4,118,673)
Net increase (decrease) in cash			13,000,547			(2,582,329)			1,781,394			1,858,199
Cash at beginning of period			23,785,771			37,587,253			35,004,924			33,146,725
Cash at end of year			36,786,318			35,004,924			36,786,318			35,004,924
Less: Cash of discontinued operations at end of year			-			2,353,123			-			2,353,123
Cash of continuing operations at end of year		$	36,786,318		$	32,651,801		$	36,786,318		$	32,651,801
Cash paid for interest and taxes
Cash paid during the period for interest		$	-		$	614,993		$	1,461,032		$	2,528,042
Cash paid during the period for taxes		$	184,791		$	16,035		$	667,262		$	214,211
Non-cash investing and financing activities:
Cashless exercise of options		$	-		$	-		$	1,315		$	5,127
Cashless exercise of warrants		$	-		$	-		$	3,901		$	16,305
Stock issued for debt conversion		$	-		$	-		$	1,000,000		$	-
Stock issued for asset acquisition		$	-		$	-		$	303,000		$	-
Stock issued for noncontingent consideration payments		$	-		$	-		$	-		$	642,000
Operating lease liabilities arising from obtaining right of use assets		$	-		$	(102,618)		$	-		$	6,372,148

About the Use of Non-GAAP Financial Measures:
To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.

Adjusted EBITDA is defined as net income (loss) attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests of discontinued operations, extraordinary litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses, stock-based compensation expense and net income from discontinued operations. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, its most directly comparable GAAP financial measure.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.

Reconciliation of Net Income (Loss) Attributable to LifeMD, Inc. Common Stockholders to Adjusted EBITDA
(in whole numbers, unaudited)
			Fourth Quarter Ended December 31,						Year Ended December 31,
			2025			2024			2025			2024
Net income (loss) attributable to LifeMD, Inc. common stockholders			$	19,187,103		$	(5,715,227)		$	11,247,856		$	(24,515,266)
Interest (income) expense (excluding amortization of debt discount)				(24,079)		510,510			1,126,598			1,773,630
Depreciation, amortization and accretion expense			1,949,727			1,647,085			7,308,458			6,203,006
Amortization of debt discount			-			100,444			234,369			401,775
Loss on debt extinguishment			-			-			1,155,851			-
Financing transactions expense			36,716			13,125			134,415			336,497
Litigation costs(a)			573,894			376,030			2,273,355			1,698,531
Severance costs			266,863			-			369,280			1,142,068
Acquisitions expenses			211,836			537,662			1,995,042			537,662
Insurance acceptance readiness			-			92,661			183,330			1,454,298
Sarbanes Oxley readiness			-			134,891			-			521,361
Taxes			176,925			598,000			208,748			598,000
Preferred stock dividends			776,562			776,562			3,106,250			3,106,250
Stock compensation expense			2,655,143			3,104,956			10,496,321			12,234,797
Net income from discontinued operations				(21,030,505)			(1,426,807)			(25,852,024)			(2,315,252)
Net (loss) income attributable to noncontrolling interests of discontinued operations				(20,697)		311,838			1,265,685			548,875
Adjusted EBITDA			$	4,759,487		$	1,061,729		$	15,253,533		$	3,726,231
(a)For the fourth quarter and year ended December 31, 2025 and 2024, the Company included costs related to: (1) a class action complaint captionedJohnston v. LifeMD, Inc., et al., against the Company and certain executive officers alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder by all defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Securities Exchange Act of 1934, as amended, by the individual officer defendants for violating their duty to disseminate accurate and truthful information, (2) a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (theMarden v. LifeMD, Inc.case), both disclosed in the Company’s Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, and (3) a heavily negotiated executive separation agreement.

FAQ

What were LifeMD's (LFMD) full year 2025 revenue and adjusted EBITDA?

LifeMD reported $194.1 million in revenue and $15.3 million adjusted EBITDA for full year 2025. According to the company, revenue rose 25% year‑over‑year and adjusted EBITDA increased 309%.

How did LifeMD perform in Q4 2025 and what were key quarterly metrics for LFMD?

Q4 2025 revenue was $46.9 million and adjusted EBITDA was $4.8 million. According to the company, active telehealth subscribers rose ~16% to about 323,000 and gross margin expanded to 87%.

What is LifeMD's cash and debt position at year‑end 2025 for LFMD?

LifeMD exited 2025 with $36.8 million in cash and reported no debt. According to the company, the strong balance sheet supports accelerated investments in growth initiatives.

What guidance did LifeMD (LFMD) give for Q1 2026 and what drives the outlook?

LifeMD expects Q1 2026 revenue of $48M–$49M and an adjusted EBITDA loss of $4M–$5M. According to the company, the loss reflects front‑loaded GLP‑1 patient acquisition investments while sign‑ups doubled versus Q4.

What is LifeMD's full year 2026 revenue and adjusted EBITDA guidance for LFMD?

For 2026 the company expects revenue of $220M–$230M (13%–19% growth) and adjusted EBITDA of $12M–$17M. According to the company, annualized run‑rate targets exceed $250M revenue and $25M adjusted EBITDA by Q4 2026.

How is LifeMD scaling its weight management and specialty offerings for LFMD?

LifeMD launched oral Wegovy post‑year‑end with >80% initiation among new weight management patients and reports record Q1 sign‑ups. According to the company, women’s health and men’s health brands are also seeing early patient growth.